• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merus N.V. CS (NQ: MRUS )

50.30 +0.37 (+0.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merus N.V. CS

< Previous 1 2 Next >
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
October 31, 2024
From Merus N.V.
Via GlobeNewswire
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
September 30, 2024
From Merus N.V.
Via GlobeNewswire
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
September 17, 2024
Petosemtamab in 2L+ HNSCC interim clinical data selected for rapid oral presentation 
From Merus N.V.
Via GlobeNewswire
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
August 06, 2024
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
August 01, 2024
From Merus N.V.
Via GlobeNewswire
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
July 24, 2024
Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback 
From Merus N.V.
Via GlobeNewswire
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
July 08, 2024
From Merus N.V.
Via GlobeNewswire
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
July 01, 2024
From Merus N.V.
Via GlobeNewswire
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
June 03, 2024
From Merus N.V.
Via GlobeNewswire
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
June 02, 2024
From Merus N.V.
Via GlobeNewswire
Merus Announces Pricing of Upsized Public Offering of Common Shares
May 29, 2024
From Merus N.V.
Via GlobeNewswire
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
May 29, 2024
From Merus N.V.
Via GlobeNewswire
Merus N.V. Announces Proposed Public Offering of Common Shares
May 28, 2024
From Merus N.V.
Via GlobeNewswire
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
May 28, 2024
From Merus N.V.
Via GlobeNewswire
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
May 23, 2024
From Merus N.V.
Via GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
May 23, 2024
From Merus N.V.
Via GlobeNewswire
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
May 13, 2024
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
May 08, 2024
From Merus N.V.
Via GlobeNewswire
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
May 06, 2024
If approved, Zeno will be the first targeted therapy for NRG1+ cancer 
From Merus N.V.
Via GlobeNewswire
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
April 24, 2024
From Merus N.V.
Via GlobeNewswire
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
April 08, 2024
From Merus N.V.
Via GlobeNewswire
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From Merus N.V.
Via GlobeNewswire
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
March 06, 2024
From Gilead Sciences, Inc.
Via Business Wire
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
March 05, 2024
Poster presentation: Monday, April 8, 2024, 9:00 am-12:30 p.m. PT 
From Merus N.V.
Via GlobeNewswire
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
March 04, 2024
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
February 28, 2024
From Merus N.V.
Via GlobeNewswire
Merus to Participate in Upcoming Investor Conferences
January 31, 2024
From Merus N.V.
Via GlobeNewswire
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
December 02, 2023
MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24 
From Merus N.V.
Via GlobeNewswire
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
November 26, 2023
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
November 02, 2023
From Merus N.V.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap